As part of intensive care, Donald Trump, who has contracted coronavirus, has received an experimental drug, a so-called antibody cocktail. It has now become known that the testing of this drug has stopped.
The head of the White House himself, after returning from the hospital, began advertising the experimental drug. The President claimed that the Regeneron Pharmaceuticals drug has accelerated his recovery. Against the backdrop of these claims, problems arose with a similar “cocktail” from Eli Lilly, which froze the trials.
“Out of cautiousness, ACTIV-3, an independent data security monitoring commission, recommended suspending the registration”, – said company spokeswoman Molly McCully. – “Lilly supports the decision of the independent DSMB to carefully ensure the safety of patients participating in this study.”
Now the Regeneron drug has also suffered the same fate. For safety reasons, the trials have been suspended. The Supervisory Board decided that the risk/benefit ratio was not in favour of the experimental cocktail.